MM21 : A multicenter, single arm, study of daratumumab-lenalidomide-dexamethasone (DRd) for newly diagnosed transplant eligible multiple myeloma patients who fail bortezomib-based induction therapy

Male or<br/>FemaleGender Male or
Female

RecruitingStatus Recruiting

Systemic<br/>Therapy TrialTypeSystemic
Therapy Trial

TwoPhase Two

18+Age Over 18

Blood<br/>CancersCancer LocationBlood
Cancers

Systemic therapy | Blood / Myeloma / LymphomaMultiple Myeloma

Trial Overview Read MoreRead more

This study evaluates the effectiveness of using a combination of therapies (Daratumumab-lenalidomide-dexamethasone) with stem cell transplant to treat patients diagnosed with Multiple Myeloma who have not responded to standard treatment.
 

This trial is treating patients with Multiple Myeloma.

This is a systemic treatment.

You may be able to join this trial if:

  • You have had a certain type of treatment or surgical procedure.
  • You have had treatment but your cancer has gotten worse or has not responded to the treatment you have been given.
  • You have had treatment, but your cancer has come back.

You may be excluded from this trial if:

  • You have a certain disease or psychological condition.
  • You have been diagnosed with a prior or secondary type of cancer.
  • You have previously been treated (or are currently being treated) on a clinical trial.

Clinical trials have complex eligibility criteria - talk to your doctor about your interest in this trial.

Clinical Summary Read MoreRead more

Trial Identifiers

Use the hyperlinks, where available to access additional clinical trial information.

Scientific Title

A multicenter, single arm, study of daratumumab-lenalidomide-dexamethasone (DRd) for newly diagnosed transplant eligible multiple myeloma patients who fail bortezomib-based induction therapy

Cooperative Group

Australasian Leukaemia and Lymphoma Group (ALLG)

Commercial Sponsor

Celgene Corporation

Summary

This study aims to assess the effectiveness of using a combination of targeted (daratumumab), immunomodulating (lenalidomide) and steroid (dexamethasone) therapies and a stem cell transplant to improve the remission and recurrence rates of Multiple Myeloma in patients that have not responded to the standard induction therapy (Bortezomib). Patients eligible to participate in this study will receive four cycles of daratumumab, lenalidomide and dexamethasone, followed by a stem cell transplant of their own non-cancerous cells and a further 12 cycles of daratumumab, lenalidomide and dexamethasone, with an additional 12 cycles of lenalidomide for maintenance.

Recruiting Hospitals Read MoreRead more

Alfred Hospital, Malignant Haematology & Stem Cell Transplantation Service
Prahran
Ms Nola Kennedy
n.kennedy@alfred.org.au
03 9076 2217

Trial Overview: General information about a clinical trial. This section provides an overview of who might be able to join this trial and what type of treatment is involved.

Next